Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.

Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T.

Cancer Discov. 2011 Aug;1(3):236-47. doi: 10.1158/2159-8290.CD-11-0073. Epub 2011 Jun 16.

PMID:
21874163
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

Berenson JR, Ma HM, Vescio R.

Semin Oncol. 2001 Dec;28(6):626-33. Review.

PMID:
11740821
[PubMed - indexed for MEDLINE]
3.

Can NF-kappaB be a target for novel and efficient anti-cancer agents?

Olivier S, Robe P, Bours V.

Biochem Pharmacol. 2006 Oct 30;72(9):1054-68. Epub 2006 Sep 14. Review.

PMID:
16973133
[PubMed - indexed for MEDLINE]
4.

Targeting NF-kappaB for colorectal cancer.

Sakamoto K, Maeda S.

Expert Opin Ther Targets. 2010 Jun;14(6):593-601. doi: 10.1517/14728221003769903. Review.

PMID:
20367537
[PubMed - indexed for MEDLINE]
5.

NF-kappaB fans the flames of lung carcinogenesis.

Wong KK, Jacks T, Dranoff G.

Cancer Prev Res (Phila). 2010 Apr;3(4):403-5. doi: 10.1158/1940-6207.CAPR-10-0042. Epub 2010 Mar 30. Review.

PMID:
20354166
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.

Freemantle SJ, Dmitrovsky E.

Cancer Prev Res (Phila). 2010 Dec;3(12):1513-8. doi: 10.1158/1940-6207.CAPR-10-0297. Review.

PMID:
21149327
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk